{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:54:28Z","timestamp":1789239268480,"version":"build-2803163510"},"reference-count":73,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T00:00:00Z","timestamp":1713398400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jiph.2024.04.016","type":"journal-article","created":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T14:22:43Z","timestamp":1713709363000},"page":"1134-1141","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy"],"prefix":"10.1016","volume":"17","author":[{"given":"Abdulaziz","family":"Boqaeid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Layqah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amgad","family":"Alonazy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8194-9483","authenticated-orcid":false,"given":"Mutaz","family":"Althobaiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al-zahraa","family":"Almahlawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Al-Roqy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Baharoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Alsaeedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinan","family":"Shamou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9277-4764","authenticated-orcid":false,"given":"Salim","family":"Baharoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jiph.2024.04.016_bib1","first-page":"171","article-title":"Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update,\" (in eng)","volume":"vol. 131","author":"Prieto-Pe\u00f1a","year":"2021","journal-title":"Pol Arch Intern Med"},{"key":"10.1016\/j.jiph.2024.04.016_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.706482","article-title":"Risk of reactivation of hepatitis B Virus (HBV) and tuberculosis (TB) and complications of Hepatitis C Virus (HCV) following tocilizumab therapy: a systematic review to inform risk assessment in the COVID-19 era","volume":"vol. 8","author":"Campbell","year":"2021","journal-title":"Front Med"},{"issue":"10","key":"10.1016\/j.jiph.2024.04.016_bib3","first-page":"1888","article-title":"Mechanisms of action of tumor necrosis factor antagonist and granulomatous infections,\" (in eng)","volume":"vol. 31","author":"Beenhouwer","year":"2004","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.jiph.2024.04.016_bib4","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: a comprehensive review,\" (in eng)","volume":"vol. 117","author":"Tracey","year":"2008","journal-title":"Pharm Ther"},{"issue":"10","key":"10.1016\/j.jiph.2024.04.016_bib5","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/S1473-3099(08)70227-5","article-title":"Tumour necrosis factor antagonists: structure, function, and tuberculosis risks,\" (in eng)","volume":"vol. 8","author":"Wallis","year":"2008","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.jiph.2024.04.016_bib6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1189\/jlb.0709517","article-title":"Infections and autoimmunity: the multifaceted relationship,\" (in eng)","volume":"vol. 87","author":"Sfriso","year":"2010","journal-title":"J Leukoc Biol"},{"issue":"1","key":"10.1016\/j.jiph.2024.04.016_bib7","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0213-9251(09)70134-0","article-title":"Tratamiento de la psoriasis en placas moderada y grave con efalizumab","volume":"vol. 24","author":"Manel Casanova","year":"2009","journal-title":"Piel"},{"issue":"3","key":"10.1016\/j.jiph.2024.04.016_bib8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/BOR.0000000000000598","article-title":"Prediction of infection risk in rheumatoid arthritis patients treated with biologics: are we any closer to risk stratification?,\" (in eng)","volume":"vol. 31","author":"Jani","year":"2019","journal-title":"Curr Opin Rheumatol"},{"issue":"9","key":"10.1016\/j.jiph.2024.04.016_bib9","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1086\/383317","article-title":"Granulomatous infectious diseases associated with tumor necrosis factor antagonists,\" (in eng)","volume":"vol. 38","author":"Wallis","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jiph.2024.04.016_bib10","first-page":"706","article-title":"Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers,\" (in eng)","volume":"vol. 34","author":"Seong","year":"2007","journal-title":"J Rheuma"},{"issue":"6","key":"10.1016\/j.jiph.2024.04.016_bib11","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","article-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis,\" (in eng)","volume":"vol. 70","author":"Buch","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jiph.2024.04.016_bib12","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1002\/art.23285","article-title":"Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade,\" (in eng)","volume":"vol. 58","author":"Wallis","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.jiph.2024.04.016_bib13","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3346\/jkms.2007.22.5.779","article-title":"Diagnosis and treatment of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea","volume":"vol. 22","author":"Yun","year":"2007","journal-title":"J Korean Med Sci"},{"issue":"10","key":"10.1016\/j.jiph.2024.04.016_bib14","first-page":"1127","article-title":"Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis,\" (in eng)","volume":"vol. 10","author":"Sichletidis","year":"2006","journal-title":"Int J Tube Lung Dis"},{"issue":"3","key":"10.1016\/j.jiph.2024.04.016_bib15","doi-asserted-by":"crossref","first-page":"340","DOI":"10.14309\/ajg.0000000000000527","article-title":"Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of Tuberculosis: A Systematic Review and Meta-Analysis,\" (in eng)","volume":"vol. 115","author":"Kedia","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.jiph.2024.04.016_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012567","article-title":"Risk of tuberculosis in patients treated with TNF-\u03b1 antagonists: a systematic review and meta-analysis of randomised controlled trials,\" (in eng)","volume":"vol. 7","author":"Zhang","year":"2017","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.jiph.2024.04.016_bib17","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR),\" (in eng)","volume":"vol. 69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.jiph.2024.04.016_bib18","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1183\/09031936.00028510","article-title":"The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement,\" (in eng)","volume":"vol. 36","author":"Solovic","year":"2010","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.jiph.2024.04.016_bib19","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1086\/517519","article-title":"Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis,\" (in eng)","volume":"vol. 195","author":"Plessner","year":"2007","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.jiph.2024.04.016_bib20","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1128\/IAI.01011-07","article-title":"Tumor necrosis factor blockade in chronic murine tuberculosis enhances granulomatous inflammation and disorganizes granulomas in the lungs,\" (in eng)","volume":"vol. 76","author":"Chakravarty","year":"2008","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.jiph.2024.04.016_bib21","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/art.27271","article-title":"Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model,\" (in eng)","volume":"vol. 62","author":"Lin","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.jiph.2024.04.016_bib22","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1086\/505430","article-title":"Tumor-Necrosis-Factor Blockers: Differential Effects on Mycobacterial Immunity","volume":"vol. 194","author":"Saliu","year":"2006","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.jiph.2024.04.016_bib23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/1756-185X.12970","article-title":"Comparison of the risk of infections in different anti-TNF agents: a meta-analysis,\" (in eng)","volume":"vol. 20","author":"Liao","year":"2017","journal-title":"Int J Rheum Dis"},{"issue":"12","key":"10.1016\/j.jiph.2024.04.016_bib24","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.3899\/jrheum.150057","article-title":"The risk of tuberculosis in patients with rheumatoid arthritis treated with tumor necrosis factor-\u03b1 antagonist: a metaanalysis of both randomized controlled trials and registry\/cohort studies,\" (in eng)","volume":"vol. 42","author":"Ai","year":"2015","journal-title":"J Rheuma"},{"issue":"6","key":"10.1016\/j.jiph.2024.04.016_bib25","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/art.20303","article-title":"Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial,\" (in eng)","volume":"vol. 50","author":"Nishimoto","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"10042","key":"10.1016\/j.jiph.2024.04.016_bib26","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0140-6736(16)30363-4","article-title":"Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial,\" (in eng)","volume":"vol. 388","author":"Bijlsma","year":"2016","journal-title":"Lancet"},{"issue":"9877","key":"10.1016\/j.jiph.2024.04.016_bib27","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(13)60250-0","article-title":"Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial,\" (in eng)","volume":"vol. 381","author":"Gabay","year":"2013","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jiph.2024.04.016_bib28","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1136\/annrheumdis-2011-201087","article-title":"Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and\/or TNF inhibitors: a large, open-label study close to clinical practice,\" (in eng)","volume":"vol. 71","author":"Bykerk","year":"2012","journal-title":"Ann Rheum Dis"},{"issue":"no. 2","key":"10.1016\/j.jiph.2024.04.016_bib29","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3109\/14397595.2013.854069","article-title":"Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data","volume":"vol. 24","author":"Nakashima","year":"2014","journal-title":"Mod Rheumatol"},{"issue":"11","key":"10.1016\/j.jiph.2024.04.016_bib30","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1002\/acr.22384","article-title":"Subcutaneous tocilizumab versus placebo in combination with disease\u2010modifying antirheumatic drugs in patients with rheumatoid arthritis,\"","volume":"vol. 66","author":"Kivitz","year":"2014","journal-title":"Arthritis care Res"},{"issue":"3","key":"10.1016\/j.jiph.2024.04.016_bib31","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10067-014-2857-y","article-title":"Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice","volume":"vol. 34","author":"Bykerk","year":"2015","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.jiph.2024.04.016_bib32","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/annrheumdis-2015-207281","article-title":"Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)","volume":"vol. 75","author":"Burmester","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jiph.2024.04.016_bib33","first-page":"625","article-title":"Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial,\" (in eng)","volume":"vol. 34","author":"Kremer","year":"2016","journal-title":"Clin Exp Rheuma"},{"issue":"12","key":"10.1016\/j.jiph.2024.04.016_bib34","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1136\/ard.2011.151092","article-title":"Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients","volume":"vol. 70","author":"Koike","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.jiph.2024.04.016_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab clinical trials","volume":"vol. 13","author":"Schiff","year":"2011","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1016\/j.jiph.2024.04.016_bib36","doi-asserted-by":"crossref","first-page":"A289","DOI":"10.1016\/j.chest.2021.07.295","article-title":"Active TB after the use of tocilizumab for COVID-19 infection","volume":"vol. 160","author":"Noh","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.jiph.2024.04.016_bib37","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/8909834","article-title":"Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted biologics","volume":"vol. 2017","author":"Cantini","year":"2017","journal-title":"Mediat Inflamm"},{"issue":"10","key":"10.1016\/j.jiph.2024.04.016_bib38","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nrrheum.2014.123","article-title":"Adverse reactions to biologic agents and their medical management","volume":"vol. 10","author":"Boyman","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.jiph.2024.04.016_bib39","series-title":"Global tuberculosis report 2012","year":"2012"},{"issue":"6","key":"10.1016\/j.jiph.2024.04.016_bib40","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.autrev.2015.01.011","article-title":"Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice,\" (in eng)","volume":"vol. 14","author":"Cantini","year":"2015","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.jiph.2024.04.016_bib41","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists,\" (in eng)","volume":"vol. 52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.jiph.2024.04.016_bib42","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.3899\/jrheum.100623","article-title":"Challenges in diagnosing latent tuberculosis infection in patients treated with tumor necrosis factor antagonists,\" (in eng)","volume":"vol. 38","author":"Keystone","year":"2011","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.jiph.2024.04.016_bib43","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jmii.2013.03.005","article-title":"Risk of tuberculosis infection in anti-TNF-\u03b1 biological therapy: from bench to bedside,\" (in eng)","volume":"vol. 47","author":"Xie","year":"2014","journal-title":"J Microbiol Immunol Infect"},{"issue":"1","key":"10.1016\/j.jiph.2024.04.016_bib44","doi-asserted-by":"crossref","first-page":"38","DOI":"10.4103\/0256-4947.59373","article-title":"Saudi guidelines for testing and treatment of latent tuberculosis infection,\" (in eng)","volume":"vol. 30","author":"Al Jahdali","year":"2010","journal-title":"Ann Saudi Med"},{"issue":"3","key":"10.1016\/j.jiph.2024.04.016_bib45","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/j.1756-185X.2012.01715.x","article-title":"Lack of adverse effect of anti-tumor necrosis factor-\u03b1 biologics in treatment of rheumatoid arthritis: 5 years follow-up,\" (in eng)","volume":"vol. 15","author":"Dewedar","year":"2012","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"10.1016\/j.jiph.2024.04.016_bib46","first-page":"41","article-title":"Risk of tuberculosis reactivation with rituximab therapy,\" (in eng)","volume":"vol. 11","author":"Alkadi","year":"2017","journal-title":"Int J Health Sci"},{"issue":"6","key":"10.1016\/j.jiph.2024.04.016_bib47","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1136\/annrheumdis-2013-204960","article-title":"Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments?","volume":"vol. 74","author":"Arkema","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.jiph.2024.04.016_bib48","first-page":"1436","article-title":"Increased risk of tuberculosis in patients with rheumatoid arthritis","volume":"vol. 30","author":"Carmona","year":"2003","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.jiph.2024.04.016_bib49","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jbspin.2010.12.004","article-title":"Incidence of tuberculosis in patients with rheumatoid arthritis. A systematic literature review,\" (in eng)","volume":"vol. 78","author":"Baronnet","year":"2011","journal-title":"Jt Bone Spine"},{"issue":"6","key":"10.1016\/j.jiph.2024.04.016_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178035","article-title":"The risk of tuberculosis disease in rheumatoid arthritis patients on biologics and targeted therapy: A 15-year real world experience in Taiwan,\" (in eng)","volume":"vol. 12","author":"Lim","year":"2017","journal-title":"PLoS One"},{"issue":"sup1","key":"10.1016\/j.jiph.2024.04.016_bib51","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","article-title":"Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis,\" (in eng)","volume":"vol. 15","author":"Minozzi","year":"2016","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"10.1016\/j.jiph.2024.04.016_bib52","first-page":"679","article-title":"Risk of tuberculosis in patients with rheumatoid arthritis in Hong Kong--the role of TNF blockers in an area of high tuberculosis burden,\" (in eng)","volume":"vol. 28","author":"Tam","year":"2010","journal-title":"Clin Exp Rheuma"},{"issue":"5","key":"10.1016\/j.jiph.2024.04.016_bib53","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","article-title":"Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection,\" (in eng)","volume":"vol. 57","author":"G\u00f3mez-Reino","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jiph.2024.04.016_bib54","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3899\/jrheum.140102","article-title":"Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance,\" (in eng)","volume":"vol. 91","author":"Cantini","year":"2014","journal-title":"J Rheuma Suppl"},{"issue":"2","key":"10.1016\/j.jiph.2024.04.016_bib55","doi-asserted-by":"crossref","DOI":"10.1590\/1806-3713\/e20190023","article-title":"Latent tuberculosis infection in patients with rheumatic diseases","volume":"vol. 45","author":"Anton","year":"2019","journal-title":"J Bras De Pneumol"},{"issue":"1","key":"10.1016\/j.jiph.2024.04.016_bib56","first-page":"20","article-title":"The prevalence of latent tuberculosis infection in patients with inflammatory arthritis and the diagnostic efficacy of different screening methods],\" (in chi)","volume":"vol. 99","author":"Liu","year":"2019","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"4","key":"10.1016\/j.jiph.2024.04.016_bib57","doi-asserted-by":"crossref","first-page":"266","DOI":"10.4103\/atm.ATM_392_16","article-title":"Pleuropulmonary manifestation in patients with rheumatoid arthritis in Saudi Arabia,\" (in eng)","volume":"vol. 12","author":"Alamoudi","year":"2017","journal-title":"Ann Thorac Med"},{"issue":"3","key":"10.1016\/j.jiph.2024.04.016_bib58","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4197\/Med.16-3.2","article-title":"The co-morbidities and mortality rate among rheumatoid arthritis patients at the western region of Saudi Arabia","volume":"vol. 16","author":"Al-Ghamdi","year":"2009","journal-title":"J King Abdulaziz Univ-Med Sci"},{"issue":"1","key":"10.1016\/j.jiph.2024.04.016_bib59","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s13075-015-0583-8","volume":"vol. 17","author":"Sakai","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"6","key":"10.1016\/j.jiph.2024.04.016_bib60","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/506935","article-title":"Antirheumatic drugs and the risk of tuberculosis,\" (in eng)","volume":"vol. 43","author":"Brassard","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"15","key":"10.1016\/j.jiph.2024.04.016_bib61","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent,\" (in eng)","volume":"vol. 345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jiph.2024.04.016_bib62","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/art.21137","article-title":"Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden,\" (in eng)","volume":"vol. 52","author":"Askling","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.jiph.2024.04.016_bib63","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry,\" (in eng)","volume":"vol. 60","author":"Tubach","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.jiph.2024.04.016_bib64","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1002\/art.11137","article-title":"Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report,\" (in eng)","volume":"vol. 48","author":"G\u00f3mez-Reino","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.jiph.2024.04.016_bib65","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard.2005.043166","article-title":"Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis,\" (in eng)","volume":"vol. 65","author":"Schiff","year":"2006","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.jiph.2024.04.016_bib66","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.crohns.2011.09.011","article-title":"Corticosteroids and immunosuppressive therapy influence the result of QuantiFERON TB Gold testing in inflammatory bowel disease patients","volume":"vol. 6","author":"Helwig","year":"2012","journal-title":"J Crohn'S Colitis"},{"issue":"RR-5","key":"10.1016\/j.jiph.2024.04.016_bib67","first-page":"1","article-title":"Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection\u2014United States, 2010","volume":"59","author":"Mazurek","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.jiph.2024.04.016_bib68","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.jiph.2024.04.016_bib69","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jaad.2008.03.023","article-title":"National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents","volume":"59","author":"Doherty","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jiph.2024.04.016_bib70","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijid.2017.03.024","article-title":"Prevalence of Latent Mycobacterium Tuberculosis Infection (LTBI) in Saudi Arabia; Population based survey","volume":"vol. 60","author":"Balkhy","year":"2017","journal-title":"Int J Infect Dis"},{"issue":"5","key":"10.1016\/j.jiph.2024.04.016_bib71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0154803","article-title":"Interferon Gamma Release Assay versus Tuberculin Skin Testing among Healthcare Workers of Highly Diverse Origin in a Moderate Tuberculosis Burden Country,\" (in eng)","volume":"vol. 11","author":"Al Hajoj","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.jiph.2024.04.016_bib72","doi-asserted-by":"crossref","first-page":"284","DOI":"10.4103\/1817-1737.157295","article-title":"The use of Quantiferon-TB gold in-tube test in screening latent tuberculosis among Saudi Arabia dialysis patients,\" (in eng)","volume":"vol. 10","author":"Al Wakeel","year":"2015","journal-title":"Ann Thorac Med"},{"key":"10.1016\/j.jiph.2024.04.016_bib73","article-title":"rheumatism: a meta-analysis and systematic review","author":"Luo","year":"2020","journal-title":"TNF-\u03b1 Inhib Can Increase risk Respir Infect when Use"}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034124001291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034124001291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,4]],"date-time":"2024-06-04T22:42:37Z","timestamp":1717540957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034124001291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":73,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1876034124001291"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2024.04.016","relation":{},"ISSN":["1876-0341"],"issn-type":[{"value":"1876-0341","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The risk of tuberculosis infection in Saudi patients receiving adalimumab, etanercept, and tocilizumab therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2024.04.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}]}}